Aims & Scope
Drug Combination Therapy (DCT) is an international peer-reviewed, open access journal sponsored by TMR publishing group. DCT aims to publish unbiased original articles, reviews, letters, news and comments in all areas of drug combination therapy. DCT is dedicated to report the latest advancements and the research done in drug combination along with all the relevant fields, including but not limited to prescription compatibility studies, disassembled formulae studies, drug compatibility synergetic/antergic mechanisms, drug incompatibility/adverse reactions, combination therapy for specific populations, integrated pharmacology studies, system/network pharmacology, big data analysis, systematic evaluation/meta-analysis, omics research, natural products chemistry, pharmaceutical analysis, etc. In order to focus on breakthrough research in a field, DCT insist on publishing special issues around a topic related to drug combination therapy.
Abstracting and Indexing
DCT has been included in CAS databases, EuroPub, J-Gate, Google Scholar, CNKI Scholar, Baidu Scholar, VIP Data, Superstar Journals Database and Traditional Medicine Research Data Expanded.
Article Processing Charges
In 2020, all accepted papers will be published free-of-charge. Drug Combination Therapy journal does not have either article processing charges or article submission charges.
The following is the editorial workflow that every manuscript submitted to the journal undergoes during the course of the peer-review process.
The entire editorial workflow is performed using the online Manuscript Tracking System. Once a manuscript is submitted for publication, the manuscript is checked by the journal’s editorial office to ensure that it is suitable to go through the normal peer review process. Once this is done, the manuscript is sent to an appropriate Editor based on the subject of the manuscript and the availability of the Editors. The science editor previews the manuscript, who does not have any potential conflict of interest with any of the manuscript’s authors.
If the Science Editor finds that the manuscript may not be of sufficient quality to go through the normal peer review process, or that the subject of the manuscript may not be appropriate for the journal’s scope, the manuscript shall be rejected with no further processing. If the Science Editor finds that the submitted manuscript is of sufficient quality and falls within the scope of the journal, they should assign the manuscript to a number of external reviewers, provided that no conflict of interests exists between these reviewers and the manuscript’s authors. The Science Editor urges the peer reviewers to complete the peer review in a timely and meaningful manner, or finds new reviewer(s); The reviewers will then submit their reports on the manuscripts along with their recommendation of one of the following actions to the Editor:
Consider after Minor Changes
Consider after Major Changes
Reject: Manuscript is flawed or not sufficiently novel
When all reviewers have submitted their reports, the editor can make one of the following editorial recommendations:
Consider after Minor Changes
Consider after Major Changes
The science editor reviews the peer reviewer’s comments; upon article resubmission, the science editor confirms whether the authors have revised the manuscript according to the peer reviewer’s comments. The science editor conducts electronic screenings to detect duplicate publications. The science editor checks all the files submitted, then sends the manuscript and all its related documents to the editorial director for further review. The editorial director evaluates the academic and language quality of the manuscript and completes the review report to be delivered to the editor-in-chief. The editor-in-chief checks whether the manuscript’s editing meets the quality standard and completes the task list to approve the manuscript’s final acceptance.
If the editor-in-chief recommends “Publish Unaltered,” the manuscript will undergo a final check by the journal’s editorial office in order to ensure that the manuscript and its review process adhere to the journal’s guidelines and policies. Once this is done, the authors will be notified of the manuscript’s acceptance.
If the editor-in-chief recommends “Consider after Minor Changes,” the authors are notified to prepare and submit a final copy of their manuscript with the required minor changes suggested by the reviewers. The editor-in-chief reviews the revised manuscript after the minor changes have been made by the authors. Once the editor-in-chief is satisfied with the final manuscript, the manuscript can be accepted.
If the editor-in-chief recommends “Consider after Major Changes,” the authors are expected to revise their manuscript in accordance with that recommendation and to submit their revised manuscript in a timely manner. Once the revised manuscript is submitted, the original reviewers are asked to review it. Along with their review reports on the revised manuscript, the reviewers make a recommendation which can be “Publish Unaltered,” “Consider after Minor Changes,” “Consider after Major Changes,” or “Reject.” Then, the Editor can make an editorial recommendation which can be “Publish Unaltered,” “Consider after Minor Changes,” or “Reject.”
If the editor-in-chief recommends rejecting the manuscript, the rejection is immediate. Also, if the majority of the reviewers recommend rejecting the manuscript, the rejection is immediate.
Peer Review Policy
Drug Combination Therapy follows a double blind peer review process to ensure impartial editorial decision-making; that is, the reviewers do not know who the authors of the manuscript are, and the authors do not have access to the information of who the peer reviewers are. All submissions to Drug Combination Therapy are assessed by an editor, who will decide whether they are suitable for peer review. If an editor is on the author list or has any other competing interest regarding a specific manuscript, another member of the Editorial Board will be assigned to assume responsibility for overseeing peer review. Submissions felt to be suitable for consideration will be sent for peer review by appropriate independent experts. Editors will make a decision based on the reviewers’ reports and authors are sent these reports along with the editorial decision on their manuscript. Authors should note that even in light of one positive report, concerns raised by another reviewer may fundamentally undermine the study and result in the manuscript being rejected.
Information for Reviewers
Authors may suggest potential reviewers if they wish; however, whether or not to consider these reviewers is at the editor's discretion. Authors should not suggest recent collaborators or colleagues who work in the same institution as themselves. Authors who wish to suggest peer reviewers can do so in the cover letter and should provide institutional email addresses where possible, or information which will help the editor to verify the identity of the reviewer.
Authors may request exclusion of individuals as peer reviewers, but they should explain the reasons in their cover letter on submission. Authors should not exclude too many individuals as this may hinder the peer review process. Please note that the editor may choose to invite excluded peer reviewers.
Intentionally falsifying information, for example, suggesting reviewers with a false name or email address, will result in rejection of the manuscript and may lead to further investigation in line with our misconduct policy.
Reviewers are therefore required to respect the confidentiality of the peer review process and not reveal any details of a manuscript or its review, during or after the peer-review process, beyond the information released by the journal. If reviewers wish to involve a colleague in the review process they should first obtain permission from the journal. The editor should be informed of the names of any individuals who assisted in the review process when the report is returned.
All articles published by Drug Combination Therapy are selected by an in-house editor and fully peer-reviewed by external reviewers. Drug Combination Therapy applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
All articles published in journals owned by the TMR Publishing Group represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.
Copyright and License
Authors retain the copyright of their manuscripts. Upon acceptance of an article, authors will be asked to complete a “License to Publish”. Acceptance of the license will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a “License to Publish” form. Permission of the journal is not required to distribution outside the institution and for all other derivative works, including compilations and translations, as long as it is not for commercial purpose. The author(s) should acknowledge that all articles published by TMR PUBLISHING GROUP LIMITED are selected by an in-house editor and fully peer-reviewed by external reviewers. TMR PUBLISHING GROUP LIMITED applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
Ownership and Management
The editing and publishing of Drug Combination Therapy are managed by TMR Publishing Group.
Drug Combination Therapy reject any advertising.
Digital Preservation Entities
The publisher is entitled to entrust digital preservation entities such as The National Library of New Zealand to archive the content of the Journal published during the term of the Publishing Agreement.
Ethical standards for publication exist to ensure high-quality scientific publications, public trust in scientific findings, and that people receive credit for their work and ideas. DCT follows the standards of Publication Ethics. We only accept manuscripts that adhere to the ethical guidelines of the Committee on Publication Ethics (COPE) and which pass strict double-blind peer review.
Code of Conduct for Publishers
Following the COPE code of conduct for publishers: The manuscript publishing process of the DCT is founded upon a clear definition of the relationship between authors, peer reviewers and our staff. That foundation is strengthened by consistent respect for the privacy of the authors and peer reviewers, protection of intellectual property and copyright, and fostering of editorial independence. All manuscripts are subject to peer review and are expected to meet standards of academic excellence. If approved by the editor, submissions will be considered by peer reviewers, whose identities will remain anonymous to the authors.
Following the COPE code of conduct for journal editors: The manuscript editing process of the DCT begins with ensuring that editors understand their general duties and responsibilities, so that they may efficiently and effectively recognize manuscripts that fit the views and scope of the journal that they represent. The manuscript editing process has systematic steps in place to assure the quality of the material selected for publication. Each step is rooted in the core values of championing freedom of maintaining integrity of the academic record, ensuring the business needs do not compromise intellectual and ethical standards, and publishing corrections, clarifications, retractions and apologies when needed. Editors and reviewers must not ask authors to include references merely to increase citations to their own or an associate’s work, to the journal, or to another journal they are associated with.
Following the Directory of Open Access Journals (DOAJ) criteria for journal indexing: DCT meet the basic requirements for indexing by the DOAJ. These basic requirements include aims, scope, editorial board members, instructions for authors, description of article quality control, open access statement, policy of dealing with plagiarism, and permission statement.
Following the academic rules and norms: Authors must provide human and animal rights statement, institutional review board statement, informed consent statement, clinical trial registration statement, institutional animal care and use committee statement, animal care and use statement, biostatistics statement, conflict-of-interest statement, and data sharing statement.
If DCT becomes aware of breaches of our publication ethics policies, whether or not the breach occurred in a journal published by TMR Publishing Group, the following sanctions may be applied across the TMR journals:
Rejection of the manuscript and any other manuscripts submitted by the author (s).
Not allowing submission for 1-3 years.
Prohibition from acting as an editor or reviewer.
DCT may apply additional sanctions for severe ethical violations.
Suspected breaches of our publication ethics policies, either before and after publication, as well as concerns about research ethics, should be reported to our Research Integrity team, overseen by the Head of Research Integrity.
Claimants will be kept anonymous if requested, though claimants may also wish to use an anonymous email service such as ProtonMail or TorGuard.
DCT may ask the authors to provide the underlying data and images, consult editors, and contact institutions or employers to ask for an investigation or to raise concerns.
Corrections and Retractions
When errors are identified in published articles, the publisher will consider what action is required and may consult the editors and the authors’ institution (s). Errors by the authors may be corrected by a corrigendum and errors by the publisher by an erratum. If there are errors that significantly affect the conclusions or there is evidence of misconduct, this may require retraction following the COPE Retraction Guidelines. All authors will be asked to agree to the content of the notice.
Conflicts of Interest
Conflicts of interest (COIs, also known as ‘competing interests’) occur when issues outside research could be reasonably perceived to affect the neutrality or objectivity of the work or its assessment. Potential conflicts of interest must be declared—whether or not they actually had an influence—to allow informed decisions. In most cases, this declaration will not stop work from being published nor will it always prevent someone from being involved in a review process.
If unsure, declare a potential interest or discuss with the editorial office. Undeclared interests may incur sanctions. Submissions with undeclared conflicts that are later revealed may be rejected. Published articles may need to be re-assessed, have a corrigendum published, or in serious cases be retracted. For more information on COIs, see the guidance from the ICMJE and WAME. Conflicts include the following:
Financial—funding and other payments, goods and services received or expected by the authors relating to the subject of the work or from an organization with an interest in the outcome of the work
Affiliations—being employed by, on the advisory board for, or a member of an organization with an interest in the outcome of the work
Intellectual property—patents or trademarks owned by someone or their organization
Personal—friends, family, relationships, and other close personal connections
Ideology—beliefs or activism, for example, political or religious, relevant to the work
Academic—competitors or someone whose work is critiqued
Authors must declare all potential interests in a ‘Conflicts of interest’ section, which should explain why the interest may be a conflict. If there are none, the authors should state “The author(s) declare(s) that there are no conflicts of interest regarding the publication of this paper.” Submitting authors are responsible for coauthors declaring their interests.
Authors must declare current or recent funding (including article processing charges) and other payments, goods or services that might influence the work. All funding, whether a conflict or not, must be declared in the ‘Acknowledgments’.
The involvement of anyone other than the authors who 1) has an interest in the outcome of the work; 2) is affiliated to an organization with such an interest; or 3) was employed or paid by a funder, in the commissioning, conception, planning, design, conduct, or analysis of the work, the preparation or editing of the manuscript, or the decision to publish must be declared.
Declared conflicts of interest will be considered by the editor and reviewers and included in the published article.
Editors and Reviewers
Editors and reviewers should decline to be involved with a submission when they
Have a recent publication or current submission with any author
Share or recently shared an affiliation with any author
Collaborate or recently collaborated with any author
Have a close personal connection to any author
Have a financial interest in the subject of the work
Feel unable to be objective
Reviewers must declare any remaining interests in the ‘Confidential’ section of the review form, which will be considered by the editor.
Editors and reviewers must declare if they have previously discussed the manuscript with the authors.
Management of Academic Misconduct
DCT strictly control academic misconduct from the time of manuscript submission. Academic misconduct includes plagiarism, Fabrication,Authorship and Acknowledgements, duplicate submission/multiple submissions, Salami publication, and Citation manipulation . We take the following measures to control academic misconduct:
Plagiarism is the appropriation of another person's thoughts, ideas, data, figures, research methods, or words without giving appropriate credit, or the over-citation of another person's published work. Manuscripts that are found to have been plagiarized from a manuscript by other authors, whether published or unpublished, will be rejected and the authors may incur sanctions. Any published articles may need to be corrected or retracted.
Fabrication is the practice of making up data or results without having performed the relevant research. The authors of submitted manuscripts or published articles that are found to have fabricated or falsified the results, including the manipulation of images, may incur sanctions, and published articles may be retracted.
Authorship and Acknowledgements
All listed authors must have made a significant scientific contribution to the research in the manuscript, approved its claims, and agreed to be an author. It is important to list everyone who made a significant scientific contribution. We refer to the ICMJE guidelines. Author contributions may be described at the end of the submission, optionally using roles defined by CRediT. Changes in authorship must be declared to the journal and agreed to by all authors.
Anyone who contributed to the research or manuscript preparation, but is not an author, should be acknowledged with their permission.
Submissions by anyone other than one of the authors will not be considered.
Duplicate Submission/Multiple Submissions
Duplicate submission/multiple submissions refers to the practice of submitting the same manuscript or several manuscripts with minor differences (e.g., differences only in title, keywords, abstract, author order, author affiliations, or a small amount of text) to two or more journals at the same time, or submitting to another journal within an agreed or stipulated period.
DCT consider only original content, i.e. articles that have not been previously published, including in a language other than English. Articles based on content previously made public only on a preprint server, institutional repository, or in a thesis will be considered.
Manuscripts submitted to DCT must not be submitted elsewhere while under consideration and must be withdrawn before being submitted elsewhere. Authors whose articles are found to have been simultaneously submitted elsewhere may incur sanctions.
If authors have used their own previously published work, or work that is currently under review, as the basis for a submitted manuscript, they must cite the previous articles and indicate how their submitted manuscript differs from their previous work. Reuse of the authors’ own words outside the Methods should be attributed or quoted in the text. Reuse of the authors’ own figures or substantial amounts of wording may require permission from the copyright holder and the authors are responsible for obtaining this.
Salami publication refers to the practice of slicing data from a large study, which could have been reported in a single paper, into different pieces and publishing them in two or more articles, all of which cover the same population, methods, and question. Redundant publication, the inappropriate division of study outcomes into more than one article (also known as salami slicing), may result in rejection or a request to merge submitted manuscripts, and the correction of published articles. Duplicate publication of the same, or a very similar, article may result in the retraction of the later article and the authors may incur sanctions.
In order to prevent citation manipulation, our science editor and editorial director check whether the manuscript’s citations meet the rules and norms; Upon discovery of citation manipulation, the manuscript will be withdrawn.